Pharming Group N.V. Q2 2026 Financial Summary
Business Context and Reporting Period
This Form 6-K filing covers the second quarter and first half of 2026, ending June 30, 2026. Pharming Group N.V. is a global biopharmaceutical company focused on rare diseases, primarily commercializing RUCONEST (for hereditary angioedema) and Joenja (leniolisib, for APDS). The company reported preliminary unaudited results and revised its full-year 2026 guidance.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | 1H 2026 | 1H 2025 |
|---|---|---|---|---|
| Total Revenue | $90.2M | $93.2M | $162.7M | $172.3M |
| Gross Profit | $75.7M | $84.2M | $141.5M | $155.0M |
| Operating Profit (Loss) | $1.3M | $10.8M | ($3.6M) | $3.8M |
| Net Profit (Loss) | $1.6M | $4.6M | ($3.6M) | ($10.3M) |
| Cash & Equivalents | $159.5M | N/A | $159.5M | $181.1M (Dec 2025) |
| Operating Cash Flow | ($9.7M) used | $11.7M generated | ($7.7M) used | $12.0M generated |
Product Breakdown (Q2 2026): RUCONEST revenue was $72.3M (down 10% YoY); Joenja revenue was $17.9M (up 40% YoY).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% in Q2 and 6% in 1H 2026, driven primarily by a 10% volume decrease in RUCONEST due to U.S. market dynamics and inventory drawdowns at specialty pharmacies.
- Profitability Impact: Operating profit dropped significantly from $10.8M to $1.3M in Q2. This was largely due to a one-time $4.9M manufacturing-related inventory impairment and $1.7M in costs associated with closing the Évreux, France production-support site.
- Adjusted Performance: Excluding the one-time impairments and closure costs, adjusted operating profit for Q2 2026 was $7.9M.
- Foreign Exchange: Finance results improved from a loss of $3.7M in Q2 2025 to a gain of $1.8M in Q2 2026, driven by a $2.9M foreign currency gain due to favorable EUR/USD movements.
Guidance, Outlook, and Risks
- Revised 2026 Guidance:
- Total Revenue: Lowered to $375M - $395M (a $30M reduction from prior guidance), anticipating 0% to 5% growth.
- Operating Expenses: Improved to $315M - $320M (a $15M improvement), reflecting structural G&A cost reductions despite over $40M in incremental R&D investment.
- Product Outlook: Management expects RUCONEST revenues to stabilize and return to growth in the second half of 2026. Joenja is expected to see accelerating growth in the U.S. and internationally, with a launch in Germany completed in July 2026 and Japan expected in Q3 2026.
- Clinical Milestones: Top-line data readouts for two Phase II trials of leniolisib in broader primary immunodeficiencies (including CVID) are expected in Q4 2026. A pediatric label expansion sNDA for Joenja (ages 4-11) has a PDUFA target date of October 24, 2026.
- Risks: Key risks include the timing of clinical readouts, regulatory approvals for pediatric indications, and the ability to execute cost reduction plans while maintaining R&D investment.
Investor Verification Checklist
- Verify the sustainability of RUCONEST patient retention (93% of year-ago levels) amidst increasing competition and U.S. market dynamics.
- Confirm the timeline and reimbursement status for Joenja launches in the EU (beyond Germany) and Japan.
- Monitor the Q4 2026 clinical data readouts for leniolisib in CVID and other PIDs to assess the potential for market expansion beyond APDS.
- Review the execution of the $9M structural G&A cost reductions and the impact of the France site closure on future manufacturing capacity.
- Assess the impact of the $4.9M inventory impairment on future cost of sales and gross margins.